Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Background Epicardial adipose tissue (EAT) is a risk factor for cardiovascular diseases.
Glucagon-like peptide 1 analogs (GLP-1A) may have beneficial cardiovascular effects and …

Background Glucagon-like peptide-1 receptor agonists have been reported to reduce body
fat as well as improving glycemic control in obese patients with type 2 diabetes. However …

We aimed to explore the relationship between GLP-1 receptor (GLP-1R) expression in
adipose tissue (AT) and incretin secretion, glucose homeostasis and weight loss, in patients …

Objective: Glucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose
improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically …

Glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are currently used for the
treatment of type 2 diabetes, have recently been proposed as anti-obesity drugs, due to their …

Incretin peptides, mainly glucagon like peptide-1 (GLP-1) and glucose-dependent
insulinotropic peptide (GIP), are gut derived hormones secreted upon cues from ingested …

The above-named article by Manning PJ, Dixit P, Satthenapalli VR, Katare R, and
Sutherland WHF (J Clin Endocrinol Metab.[published online ahead of print 21 May 2019]; …

Proglucagon-derived peptides (PGDPS) and related gut hormones exemplified by glucose-
dependent insulintropic polypeptide (GIP) regulate energy disposal and storage, through …

We aimed to explore the relationship between GLP-1 receptor (GLP-1R) expression in
adipose tissue (AT) and incretin secretion, glucose homeostasis and weight loss, in patients …